Equities research analysts at Cantor Fitzgerald initiated coverage on shares of TRex Bio (NASDAQ:TRXB – Get Free Report) in a research report issued on Tuesday, Briefing.com reports. The firm set an “overweight” rating on the stock.
Other equities research analysts have also issued research reports about the stock. JPMorgan Chase & Co. assumed coverage on shares of TRex Bio in a research note on Tuesday. They issued an “overweight” rating and a $20.00 target price on the stock. Stifel Nicolaus started coverage on TRex Bio in a research note on Tuesday. They issued a “buy” rating and a $39.00 price target for the company. Finally, Wedbush initiated coverage on TRex Bio in a report on Monday. They issued an “outperform” rating and a $30.00 price objective for the company. Four analysts have rated the stock with a Buy rating. Based on data from MarketBeat.com, TRex Bio has a consensus rating of “Buy” and an average target price of $29.67.
Check Out Our Latest Analysis on TRex Bio
TRex Bio Trading Down 0.7%
Shares of TRXB stock opened at $13.64 on Tuesday. TRex Bio has a 1-year low of $13.10 and a 1-year high of $16.56.
Insider Buying and Selling
In other TRex Bio news, major shareholder Alexandria Venture Investments bought 178,571 shares of the stock in a transaction on Tuesday, October 13th. The stock was purchased at an average price of $14.00 per share, for a total transaction of $2,499,994.00. Following the completion of the purchase, the insider directly owned 1,346,501 shares in the company, valued at approximately $18,851,014. This trade represents a 15.29% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
TRex Bio Company Profile
We are a clinical-stage biopharmaceutical company focused on tissue Treg biology for the discovery and development of immunoregulatory medicines designed to restore immune balance and promote tissue repair to address unmet needs of patients with autoimmune and inflammatory diseases. TRexBio was built on a pivotal scientific insight: that regulatory T cells (“Tregs”) in human tissue are not merely passive suppressors of inflammation, but active orchestrators of tissue immune homeostasis and repair.
Further Reading
- Five stocks we like better than TRex Bio
- AbbVie’s Humira Era Is Fading, But Its New Growth Engines Face Another Test
- GLP-1 Focus or Broader Peptide Exposure: Which ETF Has the Edge?
- Mortgage Rates Froze U.S. Housing, But These 3 Overseas Markets Still Pay Double Digits
- Big Tech Is Spending Billions on AI—These 5 Stocks Are Getting Paid
Receive News & Ratings for TRex Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TRex Bio and related companies with MarketBeat.com's FREE daily email newsletter.
